EDIT vs EPAM · rev $32.3M vs P/E 14, rev $4.73B
Editas Medicine Inc (EDIT) versus EPAM Systems Inc (EPAM) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
EPAM Systems Inc (EPAM) is a information technology services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EPAM revenue for 2024-12-31 was $4.73B. Net income was $454.5M. Revenue was up 0.8% from 2023-12-31 to 2024-12-31. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
EDIT currently screens at market cap $375.2M. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
Not investment advice. Open the EDIT and EPAM stock pages for the full models.
Not investment advice.